BSW
AVDL

Buckingham Strategic Wealth’s Avadel Pharmaceuticals AVDL Stock Holding History

Buckingham Strategic Wealth’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-13,710
Closed -$232K – 810
2024
Q1 		$232K Hold
13,710
– – ﹤0.01% 665
2023
Q4 		$194K Sell
13,710
-800
-6% -$9.4K ﹤0.01% 681
2023
Q3 		$149K Buy
14,510
+800
+6% +$10.7K ﹤0.01% 647
2023
Q2 		$226K Hold
13,710
– – ﹤0.01% 597
2023
Q1 		$98.2K Hold
13,710
– – ﹤0.01% 587
2022
Q4 		$98.2K Hold
13,710
– – ﹤0.01% 589
2022
Q3 		$69K Hold
13,710
– – ﹤0.01% 576
2022
Q2 		$33K Hold
13,710
– – ﹤0.01% 593
2022
Q1 		$94K Hold
13,710
– – ﹤0.01% 580
2021
Q4 		$111K Hold
13,710
– – ﹤0.01% 579
2021
Q3 		$134K Hold
13,710
– – ﹤0.01% 575
2021
Q2 		$92K Hold
13,710
– – ﹤0.01% 579
2021
Q1 		$124K Hold
13,710
– – 0.01% 532
2020
Q4 		$92K Buy
+13,710
New +$85.7K ﹤0.01% 522

Other funds holding AVDL

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Buckingham Strategic Wealth's AVDL Position: Q2 2024 in Review

Buckingham Strategic Wealth sold out of Avadel Pharmaceuticals (AVDL) in Q2 2024, closing a stake of 13,710 shares — an estimated $232K sold.

Buckingham Strategic Wealth first reported a position in AVDL in Q4 2020 and held it in 14 quarters. The position peaked at $232K in Q1 2024. 155 funds tracked by Wall St. Rank hold AVDL as of Q2 2024.

  • Buckingham Strategic Wealth reported no remaining Avadel Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Buckingham Strategic Wealth sold 13,710 Avadel Pharmaceuticals shares in Q2 2024, an estimated $232K.
  • Buckingham Strategic Wealth first reported a position in Avadel Pharmaceuticals in Q4 2020 and held it in 14 quarters.
  • Buckingham Strategic Wealth's Avadel Pharmaceuticals position peaked at $232K in Q1 2024.
  • 155 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2024.

Based on Buckingham Strategic Wealth's 13F filing for Q2 2024, filed 12 Aug 2024.